Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab in new-onset Giant Cell Arteritis
NCT05380453Phase 3Completed
- Sponsor
- Novartis
- Start
- Sep 2022
- Primary completion
- Feb 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of secukinumab in giant cell arteritis (GCA), sponsored by Novartis. Primary endpoint: Time from baseline to first Giant cell arteritis clinical relapse at 24 weeks. Started Sep 2022; status: completed.
02
Drugs
secukinumab
03
Conditions
giant cell arteritis (GCA)
Beyond the preview
Go deeper on NCT05380453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05380453.